Leelamine, a pyruvate dehydrogenase kinase inhibitor, can downregulate the expressions of SREBP-1 and key fatty acid synthesis enzymes (ACLY, ACC1, FASN) at the mRNA and protein levels to suppress fatty acid synthesis against PCa progression (148). The gene discussed is ACLY; the disease is posterior cortical atrophy.